Tech Company Financing Transactions
Calida Therapeutics Funding Round
Calida Therapeutics, based in Paris, secured $2.2 million in funding from AdBio Partners.
Transaction Overview
Company Name
Announced On
4/6/2023
Transaction Type
Venture Equity
Amount
$2,199,000
Round
Undisclosed
Investors
AdBio Partners (Lead Investor)
Proceeds Purpose
The company intends to use the funds to conduct additional in vivo proofs of concept and select a lead candidate.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Paris, Undisclosed
FR
Paris, Undisclosed
FR
Phone
Undisclosed
Email Address
Not Recorded
Overview
Operator of a preclinical stage biotechnology company intended to address thrombo-inflammation and vascular diseases. The company specializes in developing monoclonal antibodies to treat and prevent thrombo-inflammatory disorders by disrupting the molecular link between thrombosis and inflammation by preventing the crosstalk between platelets and myeloid cells, enabling patients to avoid tissue damage and life-threatening events by such diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Daniel Simon
Co-Founder
Clément Bertholet
Co-Founder
Edward Plow
Co-Founder
Yunmei Wang
Browse more venture capital transactions:
Prev: 4/6/2023: CND Life Sciences venture capital transaction
Next: 4/6/2023: M^ZERO Labs venture capital transaction
Share this article
Where The Data Comes From
We do our best to record all VC transactions involving tech companies. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs